Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic-Reference-Cited by-同舟云学术

Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic

Published:2017-03-06 Issue:7 Volume:49 Page:483-492
ISSN:2374-4235
Container-title:Infectious Diseases
language:en
Short-container-title:Infectious Diseases

Author:

Dash Ranjeet Prasad¹,Babu R. Jayachandra¹,Srinivas Nuggehally R.²

Affiliation:

1. Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL, USA;

2. Zydus Research Centre, Ahmedabad, India

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23744235.2017.1296968

Reference43 articles.

1. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides

2. New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents

3. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia

4. European Medicines AgencyXydalba 500 mg powder for concentrate for solution for infusion: summary of product chracteristics [Internet]. [cited 2016 Nov 16]. 2015. Available from: http://www.ema.europa.eu.

5. Durata Therapeutics US Ltd. Dalvance (dalbavancin) for injection, for intravenous use: US prescribing information [Internet]. [cited 2016 Nov 16]. 2014. Available from: http://www.dalvance.com/.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years;Enfermedades infecciosas y microbiologia clinica (English ed.);2024-05

2. Dalbavancina como tratamiento antibiótico de consolidación en endocarditis infecciosa, infección de dispositivos de estimulación cardiaca y bacteriemia: experiencia clínica de 7 años;Enfermedades Infecciosas y Microbiología Clínica;2024-03

3. Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin;Infectious Diseases and Therapy;2023-10

4. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections;Antibiotics;2023-09-28

5. Economic burden of skin and skin structure infections due to Gram-positive bacteria in patients on hospital at home-based outpatient parenteral antibiotic therapy (OPAT);Revista Española de Quimioterapia;2023-04-05